High Mortality Rates for Redo Surgery After TAVR

Courtesy of Dr. Carlos Fava.

Since the beginnings of transcatheter aortic valve replacement (TAVR) back in 2002, this strategy has gained considerable ground, encompassing not only inoperable or high-risk patients but also those at medium and low risk. Additionally, it came to include patients with failed bioprostheses.

Incidencia, características y tratamiento de la trombosis valvular post TAVI

However, there is little information on patients who require valve surgery after TAVR (something that is extremely rare).

Researchers analyzed 123 patients from the Society of Thoracic Surgeons (STS) database who required surgical aortic valve replacement after TAVR. Procedures had been conducted between 2011 and 2015.

Mean patient age was 84 years old, and 38% of subjects were female.

Patients were classified according to their STS Predicted Risk of Mortality score. In total, 17% of subjects had an STS score <4%; 24% had a score between 4% and 8%, and the remaining 59% of subjects had a score >8%.

The most common reason for surgery was paravalvular leak, followed by structural prosthetic deterioration, device sizing/position issues, and endocarditis.


Read also: SURTAVI Follow-Up Completed with Good News.


The median time between TAVR and redo surgery was 2.5 months (0.7-13).

Surgical mortality at 30 days was 17.1%. The mortality rate for low-risk patients was 14%; for medium-risk patients, 10%, and for high-risk patients, 21%.

Mortality was higher for patients with endocarditis (25%) and with leak or device sizing/position issues (24%), compared with patients with structural prosthetic deterioration (15%).

Conclusion

Surgery after TAVR failure, which is rare, is associated with a worse-than-expected prognosis compared with similar patients initially undergoing surgery. Technology development is needed to reduce the incidence of early TAVR failure and to define optimal treatment in case of failed TAVR.

Courtesy of Dr. Carlos Fava.

Original title: Reoperation After Transcatheter Aortic Valve Replacement An Analysis of the Society of Thoracic Surgeons Database.

Reference: Oliver K. Jawitz, et al. J Am Coll Cardiol Intv 2020;13:1515-1525.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...